Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 24, 2020

SELL
$13.39 - $20.73 $15,465 - $23,943
-1,155 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$15.61 - $20.44 $7,961 - $10,424
510 Added 79.07%
1,155 $23,000
Q1 2019

Apr 26, 2019

BUY
$13.15 - $18.71 $8,481 - $12,067
645 New
645 $11,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track James Investment Research Inc Portfolio

Follow James Investment Research Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of James Investment Research Inc, based on Form 13F filings with the SEC.

News

Stay updated on James Investment Research Inc with notifications on news.